Flag of the European Union EU Clinical Trials Register Help

Clinical trials for prostate cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    815 result(s) found for: prostate cancer. Displaying page 11 of 41.
    «« First « Previous 7  8  9  10  11  12  13  14  15  Next» Last»»
    EudraCT Number: 2010-022163-35 Sponsor Protocol Number: EFC11785 Start Date*: 2011-04-04
    Sponsor Name:sanofi-aventis R&D
    Full Title: Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination with Prednisone for the Treatment of Metastatic Castration Resistant Prostat...
    Medical condition: metastatic Castration Resistant Prostate Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Completed) HU (Completed) BE (Completed) ES (Completed) GB (Completed) FR (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2007-000323-17 Sponsor Protocol Number: XRP6976J/3503 Start Date*: 2007-05-29
    Sponsor Name:sanofi-aventis US
    Full Title: A Randomized, Open Label, Multicenter, Phase III, 2-Arm Study of Androgen Deprivation with Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Subjects with a Rising PSA Following...
    Medical condition: Clinically asymptomatic prostate cancer subject with a rising PSA following definitive local therapy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060862 Prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FI (Prematurely Ended) LT (Prematurely Ended) CZ (Prematurely Ended) SK (Completed) DE (Prematurely Ended) BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-004452-29 Sponsor Protocol Number: IRST185.04 Start Date*: 2017-04-12
    Sponsor Name:ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS
    Full Title: Randomized, multicentre phase II trial of the sequencing of Radium-223 and Docetaxel plus prednisone in symptomatic bone-only metastatic castration-resistant prostate cancer (mCRPC)
    Medical condition: symptomatic bone-only metastatic castration-resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10001186 Adenocarcinoma of prostate LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-000184-78 Sponsor Protocol Number: 2020110470 Start Date*: 2021-06-21
    Sponsor Name:Odense University Hospital
    Full Title: Recurrent and Metastatic Prostate Cancer: Impact of 18F-PSMA-1007 PET/CT on clinical decision making and response monitoring
    Medical condition: Metastatic Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-003827-31 Sponsor Protocol Number: ICO-N-2017-08 Start Date*: 2018-07-16
    Sponsor Name:INSTITUT DE CANCEROLOGIE DE L'OUEST
    Full Title: Prostate cancer with OligometaSTatic relapse: Combining stereotactic Ablative Radiotherapy and Durvalumab (MEDI4736), a randomized phase II trial
    Medical condition: oligometastatic hormone sensitive prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10007463 Carcinoma prostatic LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-004331-23 Sponsor Protocol Number: 212082-PCR-2023 Start Date*: 2013-07-22
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized Phase 2 Study Evaluating Abiraterone Acetate With Different Steroid Regimens for Preventing Symptoms Associated With Mineralocorticoid Excess in Asymptomatic, Chemotherapy-Naïve and Me...
    Medical condition: Metastatic Castration-Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) BE (Completed) GB (Completed) IT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2011-005168-14 Sponsor Protocol Number: UMCN-AKF11.01 Start Date*: 2012-05-14
    Sponsor Name:Radboud University Nijmegen Medical Centre
    Full Title: Lean Body Mass as a determinant of docetaxel pharmacokinetics and toxicity (LEANDOC)
    Medical condition: Exposure and toxicity of docetaxel treatment with patients with breast or metastatic castration-resistant prostate carcinoma.
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-001561-32 Sponsor Protocol Number: UC-160/1204 Start Date*: 2012-09-11
    Sponsor Name:UNICANCER
    Full Title:
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001186 Adenocarcinoma of prostate LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-003931-19 Sponsor Protocol Number: FE200486CS29 Start Date*: 2008-12-22
    Sponsor Name:Ferring Pharmaceuticals A/S
    Full Title: An Open-Label, Multi-Centre, Uncontrolled, Trial Investigating Degarelix One-Month Dosing Regimen Administered as Intermittent Androgen Deprivation (IAD) for One or More Cycles in Patients with Pro...
    Medical condition: Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Completed) FR (Completed) ES (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-000722-54 Sponsor Protocol Number: MDV3100-10(C3431013) Start Date*: 2013-10-17
    Sponsor Name:Medivation, Inc., a wholly owned subsidiary of Pfizer Inc.
    Full Title: A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study of Continued Enzalutamide Treatment Beyond Progression in Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Can...
    Medical condition: Patients With Chemotherapy Naïve Metastatic Castration Resistant Prostate Cancer.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Completed) FI (Completed) DE (Ongoing) SK (Completed) BE (Completed) SE (Completed) IT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2013-001790-25 Sponsor Protocol Number: FP01C-13-001 Start Date*: 2014-09-01
    Sponsor Name:Foresee Pharmaceuticals Co., Ltd.
    Full Title: An Open-Label, Single-Arm Study of the Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate for Injectable Suspension (LMIS 50 mg) in Subjects with Advanced Prostate Carcinoma
    Medical condition: Advanced Prostate Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10036921 Prostate carcinoma LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: AT (Completed) DE (Completed) CZ (Completed) SK (Completed) LT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2004-002882-19 Sponsor Protocol Number: MCHT001 Start Date*: 2004-12-10
    Sponsor Name:Mid Cheshire Hospitals NHS Trust
    Full Title: A controlled trial into the benefit of topical perianal glyceryl trinitrate (GTN) as a sphincter relaxant, pre-insertion of ultrasound probe for trans rectal ultrasound (TRUS) guided biopsy of the ...
    Medical condition: Prostate Cancer Diagnosis – Pain relief during biopsy
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-002987-34 Sponsor Protocol Number: CA184-437 Start Date*: 2014-12-22
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 2, Randomized, Double-Blind Study of Ipilimumab Administered at 3 mg/kg vs 10 mg/kg in Adult Subjects with Metastatic Chemotherapy-Naïve Castration Resistant Prostate Cancer Who are Asympto...
    Medical condition: Metastatic Chemotherapy-Naïve Castration Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Prematurely Ended) GB (Completed) IT (Prematurely Ended) ES (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2014-004296-22 Sponsor Protocol Number: 2014-RdC-PRO-Th Start Date*: 2015-11-10
    Sponsor Name:Centre Eugène Marquis
    Full Title: Anticholinergics impact in the treatment of acute irritative urinary toxicity during radiotherapy for prostate cancer
    Medical condition: Symptomatology related to acute urinary toxicity occuring during prostate irradiation in patients suffering from prostate cancer.
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004857 10004995 Bladder and urethral symptoms HLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-003478-30 Sponsor Protocol Number: CAAA802A12101 Start Date*: 2022-08-15
    Sponsor Name:Novartis Pharma AG
    Full Title: SatisfACtion: A Phase I/II, open-label, multi-center study of [225Ac]Ac-PSMA-R2 in men with heavily pre-treated PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) with or without...
    Medical condition: PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC) with or without prior 177Lu-PSMA radioligand therapy.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10036908 Prostatic neoplasms malignant HLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-004329-10 Sponsor Protocol Number: UKM17_0018 Start Date*: 2020-07-09
    Sponsor Name:Westfälische Wilhelms-Universität Münster c/o Universitätsklinikum Münster, Geschäftsbereich Recht u. Drittmittel
    Full Title: A Randomized, open-label, Phase 2 Study of Adjuvant Apalutamide or Standard of Care in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer After Radical Prostatectomy
    Medical condition: High risk adenocarcinoma of the prostate after radical prostatectomy (RPE)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Trial now transitioned) AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-013232-20 Sponsor Protocol Number: ISSIS40540005 Start Date*: 2009-07-22
    Sponsor Name:Dept of Urology Aarhus Universityhospital
    Full Title: An Open Phase II, Two-centre, 1-Arm Safety Study of Once-daily Orally Administered 10 mg ZD4054 in Prior Chemotherapy Treated Patients with Metastatic Hormone-resistant Prostate Cancer
    Medical condition: Castration-refractory prostate cancer prior treated with chemo therapy
    Disease: Version SOC Term Classification Code Term Level
    12.0 10036909 Prostate cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-018044-18 Sponsor Protocol Number: TaxiumII Start Date*: 2012-06-22
    Sponsor Name:Meander MC
    Full Title: A randomised phase II study of repeated Rhenium-188 HEDP combined with Docetaxel versus Docetaxel alone in castration resistant prostate cancer (CRPC) metastatic to bone’
    Medical condition: Men with castration resistant prostate cancer (CRPC) metastatic to bone
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10036921 Prostate carcinoma LLT
    16.1 100000004864 10005993 Bone metastases LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-000205-34 Sponsor Protocol Number: PR10 Start Date*: 2007-04-27
    Sponsor Name:University College London
    Full Title: Radiotherapy and Androgen Deprivation in Combination After Local Surgery. A randomised controlled trial for patients with prostate cancer.
    Medical condition: Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) DK (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2010-023382-22 Sponsor Protocol Number: 9521-CL-0002 Start Date*: 2011-02-21
    Sponsor Name:Astellas Pharma Europe B.V. (APEB)
    Full Title: Phase I/II, multi-center, open label study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of ASP9521 in patients with metastatic castrate-resistant p...
    Medical condition: metastatic castrate-resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036911 Prostate cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 7  8  9  10  11  12  13  14  15  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jul 05 10:16:02 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA